This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cingolani, H.E. Articles by Mosca, S.M. Search for Related Content PubMed PubMed Citation Articles by Cingolani, H.E. Articles by Mosca, S.M. Related Collections Animal models of human disease Genetically altered mice Ischemic biology - basic studies Genetics of cardiovascular disease

(Circulation Research. 2003;93:694.)
© 2003 American Heart Association, Inc.

Editorials

NHE-1 and NHE-6 Activities

Ischemic and Reperfusion Injury

H.E. Cingolani, I.L. Ennis, S.M. Mosca

From the Centro de Investigaciones Cardiovasculares, La Plata, Argentina.

Correspondence to Horacio E. Cingolani, MD, Centro De Investigaciones Cardiovasculares, Facultad de Ciencias Medicas, Universidad Nacional de Le Plata-60 y 120, La Plata 1900, Argentina. E-mail cicmes@infovia.com.ar

Key Words: myocardial infarction • NHE-1 • NHE-6 • apoptosis • necrosis

An extract of the first 250 words of the full text is provided, because this article has no abstract.

The study¹ published in this issue of Circulation Research showing that a null mutation of NHE-1 improves the tolerance of the heart to ischemia and reperfusion (I/R) is an important contribution for the following reasons: (1) In the animals with null mutation, contracture during the ischemic period was less and ATP levels were preserved compared with wild-type animals. This observation, on the one hand, provides evidence that protection by downregulation of NHE-1 during the ischemic period itself is indeed possible and, on the other hand, it argues against the suggestion that the exchanger is inactive during this same period.² (2) In contrast with chronic blockade of the NHE-1 by pharmacological interventions,³ the long-term absence of the exchanger does not elicit major compensatory changes that, in turn, might negate the cardioprotective effect of blocking its activity for a relative short term. This point is related to a recent publication³ showing that long-term treatment with the NHE-1 blocker cariporide is followed by an upregulation of the functional units of the exchanger in a similar way to the well-known tolerance phenomenon following ß-adrenergic receptor blockade. The absence of such upregulation negates possible hypersensitivity to ischemia upon withdrawal of the medication. The risk is evident in hearts with upregulation of NHE-1, which gain Na⁺_i more rapidly during ischemia, and show impaired recovery after reperfusion.⁴ (3) No additional protection was obtained by adding the NHE-1 blocker eniporide to the NHE-1 null mice, suggesting that there is not another NHE isoform that can be blocked with . . . [Full Text of this Article]

This article has been cited by other articles:

				C. D. Garciarena, C. I. Caldiz, M. V. Correa, G. R. Schinella, S. M. Mosca, G. E. Chiappe de Cingolani, H. E. Cingolani, and I. L. Ennis Na+/H+ exchanger-1 inhibitors decrease myocardial superoxide production via direct mitochondrial action J Appl Physiol, December 1, 2008; 105(6): 1706 - 1713. [Abstract] [Full Text] [PDF]